CECC announces ACIP's recommendations on use of Pfizer-BioNTech COVID-19 vaccine for children 6 months to 5 years of age


PublishTime:2022-08-09
On August 8, the Central Epidemic Command Center (CECC) reported that the Advisory Committee on Immunization Practices (ACIP) at the Ministry of Health and Welfare held an expert meeting in the afternoon and issued recommendations on the use of the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months through 5 years of age. The recommendations are listed below.

A. The ACIP recommends that children 6 months through 5 years of age can get vaccinated with the Pfizer-BioNTech COVID-19 vaccine, in addition to other currently recommended vaccines, in order to reduce the risk of hospitalization, severe illness (encephalitis, MIS-C) or death following infection.
B. Children in this age group are recommended to complete a 3-dose primary series (a three 3-µg dose series) in which the first two doses are administered at least four weeks apart and the third dose is given at least eight weeks after the second dose.
C. Children in this age group are recommended to complete their COVID-19 vaccine series with the same brand of vaccine.

The rollout of the Pfizer-BioNTech COVID-19 vaccine for children in this age group will be announced by the CECC in due course.